The mainstay<unk>  from<unk><unk>  leukemia is induction chemotherapy and usually includes a combination of an anthracycline and cytarabine. Induction chemotherapy sometimes includes etoposide. The decision about consolidation<unk>  depends on the risk assessment of<unk>  leukemia. Relapsed<unk><unk>  leukemia is treated with a variety of other chemotherapeutics. Novel FDA-approved agents include midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and ivosidenib. Supportive care measures include transfusions and hydration.
Acute myeloid leukemia medical therapy
Chronic myelogenous leukemia medical therapy
Myeloproliferative neoplasm medical therapy
Acute promyelocytic leukemia medical therapy
Acute lymphoblastic leukemia medical therapy
Hairy cell leukemia medical therapy
Chronic lymphocytic leukemia medical therapy
Myelodysplastic syndrome medical therapy